Deciphera reports updated data from Phase 1 ripretinib study
Deciphera reported updated data from its ongoing Phase 1 clinical study of ripretinib, a broad-spectrum KIT and PDGFRa inhibitor, in patients with second-line through fourth-line plus gastrointestinal stromal tumors, or GIST. The data includes investigator-assessed objective response rate, or ORR, by best response, disease control rate, or DCR, and median progression free survival, or mPFS, all of which were determined by Response Evaluation Criteria in Solid Tumors, or RECIST, version 1.1. Ripretinib was generally well tolerated and the updated adverse events were consistent with previously presented Phase 1 data in patients with GIST. Grade 3 or 4 treatment-emergent adverse events, or TEAEs, in greater than 5% of patients were lipase increased, anemia, hypertension and abdominal pain. A total of 13% of patients experienced TEAEs leading to study treatment discontinuation, 17% of patients experienced TEAEs leading to dose reduction and 49% of patients had TEAEs leading to study drug interruption.